Related Experiment Video
Updated: Dec 8, 2025
12:42
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
10.0K
Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
Giorgio Frega1,2,3, Qi Wu1,2, Julie Le Naour1,2
1Equipe labellisée par la Ligue Contre le Cancer, Université de Paris, Sorbonne Université, INSERM UMR1138, Centre de Recherche des Cordeliers, Paris, France.
Oncoimmunology
|September 16, 2020
Summary
Resiquimod and motolimod, Toll-like receptor 7/8 agonists, show promise as cancer immunotherapies. These compounds enhance immune responses, supporting their investigation in combination with various cancer vaccines.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Imiquimod, an established imidazoquinoline, paved the way for developing novel immunostimulatory agents.
- Resiquimod (R848) and motolimod (VTX-2337) are advanced derivatives targeting Toll-like receptor 7 (TLR7) and/or TLR8.
Purpose of the Study:
- To review preclinical and clinical evidence for resiquimod, motolimod, and other TLR7/TLR8 agonists.
- To support their development as anticancer agents, particularly when combined with cancer vaccines.
Main Methods:
- Summary of existing preclinical research.
- Analysis of ongoing and completed clinical trials.
- Evaluation of TLR7/TLR8 agonists' adjuvant-like activity in antigen-presenting cells (APCs).
Main Results:
- Resiquimod and motolimod function as agonists of TLR7/TLR8, providing adjuvant signals to APCs.
- These agents are being explored for treating various cancers, often in conjunction with diverse vaccine platforms.
Conclusions:
- TLR7/TLR8 agonists demonstrate potential as immunostimulatory agents in oncology.
- Combination strategies involving these agonists and cancer vaccines are a key area of ongoing research.
Related Concept Videos
01:27Tumor Immunotherapy
1.4K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.4K
02:57Targeted Cancer Therapies
8.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.4K
02:56Treatment Resistant Cancers
3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.6K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.6K